Skip to main content
Erschienen in: Annals of Nuclear Medicine 6/2018

15.05.2018 | Original Article

Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer

verfasst von: Shinji Ito, Shingo Iwano, Katsuhiko Kato, Shinji Naganawa

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

To identify prognostic factors associated with a low-iodine diet (LID) and the amount of remnant thyroid tissue in Japanese patients with differentiated thyroid cancer (DTC) who received initial I-131 remnant ablation (RAI) using a fixed low dose of I-131 (1110 MBq).

Patients and methods

In this prospective study, we enrolled 45 patients. Patients were classified into a self-managed LID group and a strict LID group. We measured the urinary iodine concentration on the day of RAI after patients consumed LID for 2 weeks. Thyroid-stimulating hormone-induced thyroglobulin (Tg) levels and I-131 uptake by the remnant thyroid tissue were also evaluated. A response-evaluation whole-body scan (WBS) was performed 6–8 months after RAI to determine the outcome of the therapy.

Results

Post-LID urinary iodine levels of the strict LID group tended to be lower than those of the self-managed LID group. Twenty-five cases (56%) showed absence of uptake, whereas 20 cases (44%) showed residual uptake on the response-evaluation WBS. There were no significant differences between “absence” and “residual” groups in urinary iodine concentrations and Tg levels (p = 0.253 and p = 0.234, respectively). However, significant differences were observed in I-131 uptake by the thyroid bed (p = 0.035).

Conclusions

For patients following the current Japanese method of a 2-week LID, the urinary iodine concentration was not a predictive factor for the successful outcome of RAI. In contrast, low I-131 uptake by the thyroid bed, revealed by the scintigram after RAI, may serve as a favorable predictive factor.
Literatur
1.
Zurück zum Zitat Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.CrossRefPubMed Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.CrossRefPubMed
2.
Zurück zum Zitat Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100(4):1529–36.CrossRefPubMedPubMedCentral Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100(4):1529–36.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59.CrossRefPubMed Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59.CrossRefPubMed
4.
Zurück zum Zitat Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2003;58(4):428–35.CrossRef Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2003;58(4):428–35.CrossRef
5.
Zurück zum Zitat Delange F. Iodine deficiency in Europe and its consequences: an update. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S404-16.PubMed Delange F. Iodine deficiency in Europe and its consequences: an update. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S404-16.PubMed
6.
Zurück zum Zitat Gartner R. Recent data on iodine intake in Germany and Europe. J Trace Elem Med Biol. 2016;37:85–9.CrossRefPubMed Gartner R. Recent data on iodine intake in Germany and Europe. J Trace Elem Med Biol. 2016;37:85–9.CrossRefPubMed
7.
Zurück zum Zitat Nagataki S. The average of dietary iodine intake due to the ingestion of seaweeds is 1.2 mg/day in Japan. Thyroid. 2008;18(6):667–8.CrossRefPubMed Nagataki S. The average of dietary iodine intake due to the ingestion of seaweeds is 1.2 mg/day in Japan. Thyroid. 2008;18(6):667–8.CrossRefPubMed
8.
Zurück zum Zitat Lim CY, Kim JY, Yoon MJ, Chang HS, Park CS, Chung WY. Effect of a low iodine diet vs. restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients. Yonsei Med J. 2015;56(4):1021–7.CrossRefPubMedPubMedCentral Lim CY, Kim JY, Yoon MJ, Chang HS, Park CS, Chung WY. Effect of a low iodine diet vs. restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients. Yonsei Med J. 2015;56(4):1021–7.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Dobrenic M, Huic D, Zuvic M, Grosev D, Petrovic R, Samardzic T. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial results. Radiol Oncol. 2011;45(3):189–95.CrossRefPubMedPubMedCentral Dobrenic M, Huic D, Zuvic M, Grosev D, Petrovic R, Samardzic T. Usefulness of low iodine diet in managing patients with differentiated thyroid cancer - initial results. Radiol Oncol. 2011;45(3):189–95.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med. 1999;26(11):1448–52.CrossRefPubMed Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med. 1999;26(11):1448–52.CrossRefPubMed
11.
Zurück zum Zitat Grunwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med. 1996;37(12):1962–4.PubMed Grunwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med. 1996;37(12):1962–4.PubMed
12.
Zurück zum Zitat Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery. 1999;126(1):13–9.CrossRefPubMed Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery. 1999;126(1):13–9.CrossRefPubMed
13.
Zurück zum Zitat Park HJ, Jeong GC, Kwon SY, Min JJ, Bom HS, Park KS, et al. Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma. Nucl Med Mol Imaging. 2014;48(4):255–61.CrossRefPubMedPubMedCentral Park HJ, Jeong GC, Kwon SY, Min JJ, Bom HS, Park KS, et al. Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma. Nucl Med Mol Imaging. 2014;48(4):255–61.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Lang BH, Wong KP, Wan KY. Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma. Ann Surg Oncol. 2013;20(2):653–9.CrossRefPubMed Lang BH, Wong KP, Wan KY. Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma. Ann Surg Oncol. 2013;20(2):653–9.CrossRefPubMed
15.
Zurück zum Zitat Ciappuccini R, Hardouin J, Heutte N, Vaur D, Quak E, Rame JP, et al. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden. Eur J Endocrinol. 2014;171(2):247–52.CrossRefPubMed Ciappuccini R, Hardouin J, Heutte N, Vaur D, Quak E, Rame JP, et al. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden. Eur J Endocrinol. 2014;171(2):247–52.CrossRefPubMed
16.
Zurück zum Zitat Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, Sparks JC, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med. 1983;8(3):123–6.CrossRefPubMed Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, Sparks JC, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med. 1983;8(3):123–6.CrossRefPubMed
17.
Zurück zum Zitat Ohashi T, Yamaki M, Pandav CS, Karmarkar MG, Irie M. Simple microplate method for determination of urinary iodine. Clin Chem. 2000;46(4):529–36.PubMed Ohashi T, Yamaki M, Pandav CS, Karmarkar MG, Irie M. Simple microplate method for determination of urinary iodine. Clin Chem. 2000;46(4):529–36.PubMed
18.
Zurück zum Zitat Park JT, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine. Thyroid. 2004;14(1):57–63.CrossRefPubMed Park JT, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine. Thyroid. 2004;14(1):57–63.CrossRefPubMed
19.
Zurück zum Zitat Tomoda C, Uruno T, Takamura Y, Ito Y, Miya A, Kobayashi K, et al. Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy. Endocr J. 2005;52(2):237–40.CrossRefPubMed Tomoda C, Uruno T, Takamura Y, Ito Y, Miya A, Kobayashi K, et al. Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy. Endocr J. 2005;52(2):237–40.CrossRefPubMed
20.
Zurück zum Zitat Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–73.CrossRefPubMed Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–73.CrossRefPubMed
21.
Zurück zum Zitat Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–85.CrossRefPubMed Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–85.CrossRefPubMed
22.
Zurück zum Zitat Zhang Y, Liang J, Yang X, Yang K, Lin Y. Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin. Nucl Med Commun. 2015;36(6):553–9.CrossRefPubMed Zhang Y, Liang J, Yang X, Yang K, Lin Y. Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin. Nucl Med Commun. 2015;36(6):553–9.CrossRefPubMed
23.
Zurück zum Zitat Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun. 2012;33(3):275–82.CrossRefPubMed Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun. 2012;33(3):275–82.CrossRefPubMed
24.
Zurück zum Zitat Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab. 2004;89(4):1666–73.CrossRefPubMed Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab. 2004;89(4):1666–73.CrossRefPubMed
25.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
Metadaten
Titel
Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer
verfasst von
Shinji Ito
Shingo Iwano
Katsuhiko Kato
Shinji Naganawa
Publikationsdatum
15.05.2018
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 6/2018
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-018-1261-0

Weitere Artikel der Ausgabe 6/2018

Annals of Nuclear Medicine 6/2018 Zur Ausgabe